Literature DB >> 23597073

The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide.

Wennan Du1, Shumao Sun, Yu Xu, Jie Li, Chunhui Zhao, Bifei Lan, Hao Chen, Lingyun Cheng.   

Abstract

PURPOSE: To determine the capacity and kinetics of the binding between triamcinolone acetonide (TA) and the ocular pigment for a better understanding of the transscleral delivery.
METHODS: In the in vitro study, natural melanin (sepia officinalis, Sigma-Aldrich) was incubated at 37°C with different concentrations of TA and the binding capacity/binding affinity was measured. The TA releasing profile from the melanin was also studied through repeated incubation of TA-melanin in fresh phosphate-buffed saline. In the ex vivo study, the effect of the choroidal pigment on the trans sclera/choroid permeability of TA was investigated through Franz-type vertical diffusion cells using both a TA suspension and a saturated TA solution.
RESULTS: The amount of TA bound to melanin increases with the increase of the TA concentration and with an increase in the incubation time. A Scatchard analysis revealed that the maximum number of moles of TA bound to melanin is predicted to be 22.43 nmol/mg, with a binding affinity of K=2.4×10(-5) nM(-1). TA released from a pigment showed a fast phase within the first 24 h and a slow phase thereafter. About 40% of the bound TA released in the first day and 73.94% of accumulative release was observed after 5 days. The TA suspension showed more TA penetration through the scleral-choroid complex than the saturated solution (P=0.0104). The apparent permeability coefficients for the suspension across the sclera-choroid of pigmented and albino rabbits are 7.48±1.53×10(-6) cm/s and 10.78±2.49×10(-6) cm/s, respectively.
CONCLUSIONS: TA can bind to and release from the ocular pigment, which may extend the TA ocular half-life and therapeutic duration when TA is delivered through a subtenon injection. A further in vivo study is warranted to validate the findings and to quantitate the magnitude of the difference between pigmented and albino animals.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23597073      PMCID: PMC3757532          DOI: 10.1089/jop.2012.0226

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  29 in total

1.  Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.

Authors:  Lingyun Cheng; Karl Y Hostetler; Jeffery Lee; Hyoung Jun Koh; James R Beadle; Kenichiro Bessho; Mitsuko Toyoguchi; Kathy Aldern; Jean-Marc Bovet; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-11       Impact factor: 4.799

2.  Binding characteristics of drugs to synthetic levodopa melanin.

Authors:  K Shimada; R Baweja; T Sokoloski; P N Patil
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

3.  Comparison of intraocular pressure elevation after anterior versus posterior subtenon triamcinolone acetonide acetate injection: a retrospective study.

Authors:  Xiaoling Liu; Yingzi Li; Yin Zhang; Wennan Du; Shumao Sun; Bing Lin; Hao Chen; Lingyun Cheng
Journal:  Retina       Date:  2012-10       Impact factor: 4.256

4.  Diffusion of high molecular weight compounds through sclera.

Authors:  J Ambati; C S Canakis; J W Miller; E S Gragoudas; A Edwards; D J Weissgold; I Kim; F C Delori; A P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-04       Impact factor: 4.799

5.  Ocular toxicity of beta-blockers and benzalkonium chloride in pigmented rabbits: electrophysiological and morphological studies.

Authors:  A Chou; S Hori; M Takase
Journal:  Jpn J Ophthalmol       Date:  1985       Impact factor: 2.447

6.  Ocular kinetics of pefloxacin after intramuscular administration in albino and pigmented rabbits.

Authors:  I Cochereau-Massin; J Bauchet; F Faurisson; J M Vallois; P Lacombe; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

7.  Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis.

Authors:  A A Okada; T Wakabayashi; Y Morimura; S Kawahara; E Kojima; Y Asano; T Hida
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

8.  Binding affinity of bunazosin, dorzolamide, and timolol to synthetic melanin.

Authors:  Yoshiaki Kiuchi; Nobue Terakawa; Tomoko Nakata; Kunio Yamasaki; Yoshihiro Saito; Nami Ito; Kohei Okada
Journal:  Jpn J Ophthalmol       Date:  2004 Jan-Feb       Impact factor: 2.447

9.  Binding characteristics of fluoroquinolones to synthetic levodopa melanin.

Authors:  Chiho Ono; Makoto Tanaka
Journal:  J Pharm Pharmacol       Date:  2003-08       Impact factor: 3.765

10.  Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.

Authors:  Karen G Carrasquillo; Joseph A Ricker; Ioannis K Rigas; Joan W Miller; Evangelos S Gragoudas; Anthony P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-01       Impact factor: 4.799

View more
  1 in total

1.  A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells.

Authors:  Yoo Chun Kim; Henry T Hsueh; Matthew D Shin; Cynthia A Berlinicke; Hyounkoo Han; Nicole M Anders; Avelina Hemingway; Kirby T Leo; Renee Ti Chou; HyeYoung Kwon; Matthew B Appell; Usha Rai; Patricia Kolodziejski; Charles Eberhart; Ian Pitha; Donald J Zack; Justin Hanes; Laura M Ensign
Journal:  Drug Deliv Transl Res       Date:  2021-04-26       Impact factor: 4.617

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.